Tafenoquine for malaria in children in Papua New Guinea
Treatments studied
Part of Infections clinical trials.
This study tests a single dose of tafenoquine (an antimalarial medicine) in children from Papua New Guinea who have uncomplicated malaria. It aims to see how the drug works in children who have normal G6PD activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have malaria that is confirmed by a test and is not severe (no serious symptoms like confusion or trouble breathing)
- You have had a blood test showing your G6PD enzyme is normal (over 70% activity)
- You are not allergic to primaquine, artemether-lumefantrine, or dihydroartemisinin-piperaquine
- You are able to attend all the study follow-up visits
- You do not have any other significant medical condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how the malaria medicine tafenoquine works in healthy children in Papua New Guinea. It may help find the right dose to prevent malaria safely.
This study measures how a medicine called an 8-aminoquinoline passes into breast milk after birth, to help prevent malaria in new mothers. If you and your baby have normal G6PD levels and you plan to exclusively breastfeed, this trial may be for you.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
This trial tests whether adding the drug tafenoquine to standard malaria treatment can prevent the return of P. vivax malaria. It is for adults who have a normal G6PD enzyme level and are healthy enough to participate.
This study tests how the body processes a single dose of the antimalarial drug tafenoquine in healthy adults. It will help doctors understand how the drug works and how it is broken down, which may lead to better ways to prevent malaria.
Hear when a new Uncomplicated Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.